Drug Profile
BIIB 063
Alternative Names: anti-CD40 - Biogen; BIIB063Latest Information Update: 26 Dec 2017
Price :
$50
*
At a glance
- Originator Biogen
- Class Monoclonal antibodies
- Mechanism of Action CD40 ligand inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Sjogren's syndrome
Most Recent Events
- 03 Nov 2017 Pharmacokinetics, pharmacodynamics and immunogenicity data from a phase I SAD trial in Healthy volunteers presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting (ACR/ARHP-2017)
- 17 Apr 2017 Biogen terminates phase I trial in healthy volunteers in United Kingdom, due to preclinical safety findings in non-human primates (SC, IV) (NCT02555085)